HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Determining maximal tolerable dose of the monoclonal antibody BR96 labeled with 90Y or 177Lu in rats: establishment of a syngeneic tumor model to evaluate means to improve radioimmunotherapy.

AbstractPURPOSE:
To evaluate therapeutic strategies, it is essential to use biological models reflecting important aspects of the clinical situation. The aim of the present study was to compare the maximal tolerable dose of the monoclonal antibody BR96 labeled with 90Y or 177Lu in immunocompetent rats. Maximal tolerable dose was defined as the highest activity that allows 100% of the animals to survive without clinical signs, such as infections, bleeding, or diarrhea, and with <20% loss in body weight.
EXPERIMENTAL DESIGN:
Increasing activity levels of BR96 labeled with 90Y or 177Lu were administered to groups of rats. Blood parameters, body weight, and general performance were monitored for 8 weeks.
RESULTS:
Two days postinjection, all groups had decreased leukocyte counts down to 5% to 15% of initial values. Initiation of recovery (at 14-21 days) showed a dose-response relationship. All groups, except the group given the highest activity of 90Y, had complete resolution in their leukopenia. The decrease in platelets was delayed to days 7 to 14 postinjection with a dose-dependent response regarding both severity of the nadir (10-40% of initial value) and the start of recovery. Animals in the groups given the highest activities of both 90Y and 177Lu exhibited skin infections on day 21.
CONCLUSIONS:
The results showed good reproducibility and dose-dependent toxicity for both radionuclides, indicating that the maximal tolerable dose for 177Lu-BR96 (1,000 MBq/kg) is 1.7 times that for 90Y-BR96 (600 MBq/kg) in rats. This model makes it feasible to evaluate strategies to escalate therapeutic doses to tumors without increasing normal tissue toxicity.
AuthorsLinda Mårtensson, Zhongmin Wang, Rune Nilsson, Tomas Ohlsson, Peter Senter, Hans-Olov Sjögren, Sven-Erik Strand, Jan Tennvall
JournalClinical cancer research : an official journal of the American Association for Cancer Research (Clin Cancer Res) Vol. 11 Issue 19 Pt 2 Pg. 7104s-7108s (Oct 01 2005) ISSN: 1078-0432 [Print] United States
PMID16203809 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Monoclonal
  • BR96 monoclonal antibody
  • Chelating Agents
  • Heterocyclic Compounds, 1-Ring
  • Radioisotopes
  • Radiopharmaceuticals
  • Yttrium Radioisotopes
  • 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid
  • Lutetium
  • Biotin
Topics
  • Animals
  • Antibodies, Monoclonal (biosynthesis, chemistry, therapeutic use)
  • Biotin (chemistry)
  • Body Weight
  • Brain (pathology)
  • Chelating Agents (pharmacology)
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Heterocyclic Compounds, 1-Ring (pharmacology)
  • Leukocytes (cytology, drug effects)
  • Lutetium (therapeutic use)
  • Maximum Tolerated Dose
  • Platelet Count
  • Radioimmunotherapy (methods)
  • Radioisotopes (therapeutic use)
  • Radionuclide Imaging
  • Radiopharmaceuticals (therapeutic use)
  • Rats
  • Time Factors
  • Yttrium Radioisotopes (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: